Form 10-Q Spero Therapeutics, Inc. For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
TD Cowen Upgrades Spero Therapeutics (SPRO) to Buy
August 6, 2024 7:22 AM EDTTD Cowen analyst Ritu Baral upgraded Spero Therapeutics (NASDAQ: SPRO) from Hold to Buy.
The analyst comments "2Q24: We are upgrading SPRO to Buy on new clarity on catalyst timing and optimism for '720 Ph2a data in the 2nd half of... More
